David A. Siegel Arvinas, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arvinas, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 227,600 shares of ARVN stock, worth $4.26 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
227,600
Previous 41,700
445.8%
Holding current value
$4.26 Million
Previous $1.11 Million
404.95%
% of portfolio
0.01%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ARVN
# of Institutions
229Shares Held
68.4MCall Options Held
226KPut Options Held
285K-
Vanguard Group Inc Valley Forge, PA7.01MShares$131 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$126 Million7.19% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$117 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.85MShares$72.2 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.78MShares$52.1 Million1.09% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $997M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...